Works by Prawjaeng, Juthamas

Results: 7

A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand.
Published in:
Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-81747-7
By:
- Chitpim, Natthakan;
- Leelahavarong, Pattara;
- Prawjaeng, Juthamas;
- Ittiphisit, Sakditat;
- Srinonprasert, Varalak;
- Kongmalai, Tanawan
Publication type:
Article
Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis: A Cost-Utility Analysis of Onasemnogene Abeparvovec and Risdiplam for SMA Treatment: S. Khuntha et al.
Published in:
Applied Health Economics & Health Policy, 2025, v. 23, n. 2, p. 277, doi. 10.1007/s40258-024-00915-y
By:
- Khuntha, Sarayuth;
- Prawjaeng, Juthamas;
- Ponragdee, Kunnatee;
- Sanmaneechai, Oranee;
- Srinonprasert, Varalak;
- Leelahavarong, Pattara
Publication type:
Article
Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.
Published in:
Applied Health Economics & Health Policy, 2021, v. 19, n. 4, p. 463, doi. 10.1007/s40258-021-00661-5
By:
- Painter, Chris;
- Isaranuwatchai, Wanrudee;
- Prawjaeng, Juthamas;
- Wee, Hwee Lin;
- Chua, Brandon Wen Bing;
- Huynh, Vinh Anh;
- Lou, Jing;
- Goh, Fang Ting;
- Luangasanatip, Nantasit;
- Pan-Ngum, Wirichada;
- Yi, Wang;
- Clapham, Hannah;
- Teerawattananon, Yot
Publication type:
Article
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
Published in:
European Journal of Health Economics, 2023, v. 24, n. 5, p. 735, doi. 10.1007/s10198-022-01505-2
By:
- Wang, Yi;
- Luangasanatip, Nantasit;
- Pan–ngum, Wirichada;
- Isaranuwatchai, Wanrudee;
- Prawjaeng, Juthamas;
- Saralamba, Sompob;
- Painter, Christopher;
- Briones, Jamaica Roanne;
- Teerawattananon, Yot
Publication type:
Article
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
Published in:
BMC Health Services Research, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12913-023-09595-1
By:
- Prawjaeng, Juthamas;
- Leelahavarong, Pattara;
- Budtarad, Nuttakarn;
- Pilasant, Songyot;
- Chanjam, Chonticha;
- Katchamart, Wanruchada;
- Narongroeknawin, Pongthorn;
- Kitumnuaypong, Tasanee
Publication type:
Article
Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis.
Published in:
Asian Pacific Journal of Allergy & Immunology, 2022, v. 40, n. 4, p. 321, doi. 10.12932/ap-121122-1501
By:
- Angkasekwinai, Nasikarn;
- Prawjaeng, Juthamas;
- Leelahavarong, Pattara;
- Khuntha, Sarayuth;
- Pheerapanyawaranun, Chatkamol;
- Chitpim, Natthakan;
- Srinonprasert, Varalak;
- Chokephaibulkit, Kulkanya
Publication type:
Article
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients: T. Kongmalai et al.
Published in:
PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 69, doi. 10.1007/s41669-024-00526-2
By:
- Kongmalai, Tanawan;
- Prawjaeng, Juthamas;
- Hadnorntun, Phorntida;
- Leelahavarong, Pattara;
- Chaikledkaew, Usa;
- Thakkinstian, Ammarin;
- Srinonprasert, Varalak
Publication type:
Article

Works by Prawjaeng, Juthamas

A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand.

Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis: A Cost-Utility Analysis of Onasemnogene Abeparvovec and Risdiplam for SMA Treatment: S. Khuntha et al.

Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.

Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.

Binding and neutralizing antibody levels and vaccine efficacy/effectiveness compared between heterologous and homologous primary series COVID-19 vaccination: A systematic review and meta-analysis.

Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients: T. Kongmalai et al.